Contrasting Voyager Therapeutics (NASDAQ:VYGR) and Alvotech (NASDAQ:ALVO)

Alvotech (NASDAQ:ALVO) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Insider and Institutional Ownership

48.0% of Voyager Therapeutics shares are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 6.4% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Alvotech and Voyager Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alvotech	12.12%	-26.10%	5.28%
Voyager Therapeutics	-404.85%	-48.94%	-37.38%

Volatility and Risk

Alvotech has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.

Earnings & Valuation

This table compares Alvotech and Voyager Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$491.98 million	3.01	-$231.86 million	$0.23	21.39
Voyager Therapeutics	$31.32 million	6.68	-$65.00 million	($2.16)	-1.74

Voyager Therapeutics has lower revenue, but higher earnings than Alvotech. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Alvotech and Voyager Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2	2	2	0	2.00
Voyager Therapeutics	1	0	5	0	2.67

Alvotech presently has a consensus target price of $8.60, suggesting a potential upside of 74.80%. Voyager Therapeutics has a consensus target price of $13.75, suggesting a potential upside of 265.69%. Given Voyager Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Alvotech.

Summary

Voyager Therapeutics beats Alvotech on 8 of the 14 factors compared between the two stocks.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

About Voyager Therapeutics

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.